NMNobuhiko Makino

Nobuhiko Makino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nobuhiko Makino has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Diabetes on the Efficacy of Low‐Voltage Area Ablation for Persistent Atrial Fibrillation: A Subanalysis of the SUPPRESS‐AF Trial

    by Tatsuhisa Ozaki, Koichi Inoue, Tsuyoshi Mishima, Takuya Ohashi, Satoshi Osaki, Yasunori Ueda, Masaharu Masuda, Akihiro Sunaga, Nobuaki Tanaka, Tetsuya Watanabe, et al.

    Background: The potential value of low‐voltage area (LVA) ablation for persistent atrial fibrillation (AF) has been suggested. However, its efficacy determinants remain unclear. We investigated the impact of diabetes on the outcomes of LVA ablation in patients with persistent AF. Methods: This post hoc subanalysis of the multicenter randomized controlled trial SUPPRESS‐AF (Efficacy and Safety of Low‐Voltage‐Guided Ablation for Recurrence Prevention Compared With Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation) included patients with persistent AF undergoing initial ablation. Following pulmonary vein isolation (PVI), patients with LVAs were randomized to PVI+LVA‐ablation or PVI alone. We compared recurrence‐free survival between patients with and without diabetes. The primary end point was freedom from AF/atrial tachycardia recurrence. Results: Of 1347 patients with persistent AF, 343 (25.5%) had left atrial LVAs. The nondiabetic group comprised 264 patients (136 and 128 in the PVI‐alone and PVI+LVA‐ablation arms, respectively), and the diabetic group comprised 77 patients (35 and 42 in each arm, respectively). No significant difference was observed in LVA extent between the groups. Overall recurrence rates were also similar (44% versus 42%; P =0.658). In the nondiabetic group, the PVI+LVA‐ablation arm showed significantly lower recurrence rates compared with the PVI‐alone arm (35% versus 49%; P =0.018). Conversely, patients with diabetes exhibited higher recurrence rates in the PVI+LVA‐ablation arm compared with those in the PVI‐alone arm (48% versus 40%; P =0.290). A significant interaction was observed between diabetes status and LVA ablation efficacy ( P for interaction=0.041). Conclusions: In this exploratory post hoc analysis, LVA ablation may benefit patients without diabetes, whereas no clear benefit, and a possible signal of futility, was observed in patients with diabetes.


  • Open Access

    Efficacy of Low‐Voltage Area Ablation Across Substrate Size in Persistent Atrial Fibrillation: A Post Hoc Analysis of the SUPPRESS‐AF Randomized Trial

    by Masato Okada, Daisuke Sakamoto, Masaharu Masuda, Nobuaki Tanaka, Tetsuya Watanabe, Hitoshi Minamiguchi, Yasuyuki Egami, Takafumi Oka, Tomoko Minamisaka, Masato Kawasaki, et al.

    Background: Larger low‐voltage areas (LVAs) in the left atrium are associated with increased arrhythmia recurrence after atrial fibrillation (AF) ablation. The benefit of adjunctive LVA ablation may therefore depend on substrate extent. This study examined the efficacy of LVA ablation across a spectrum of LVA sizes in persistent AF. Methods: The SUPPRESS‐AF (Efficacy and Safety of Left Atrial Low‐Voltage Area Guided Ablation for Recurrence Prevention Compared to Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation) trial screened 1364 patients undergoing initial ablation for persistent AF, of whom 342 with left atrial LVAs (≥5 cm 2 ) were randomized to pulmonary vein isolation with or without adjunctive LVA ablation. In the 341 analyzed patients, LVA size was categorized as small (2 , n=106), moderate (≥10 to 2 , n=127), or extensive (≥20 cm 2 , n=108). The primary end point was recurrence of AF or atrial tachycardia within 1 year without antiarrhythmic drugs. Treatment effects across LVA sizes were evaluated using a Cox model with restricted cubic splines. Results: AF/atrial tachycardia recurrence rates were similar between the pulmonary vein isolation+LVA ablation and pulmonary vein isolation‐alone groups in patients with small (38.5% versus 29.6%; P =0.28) and moderate LVA sizes (40.6% versus 53.5%; P =0.15). However, adjunctive LVA ablation significantly reduced recurrence in patients with extensive LVAs (34.7% versus 57.6%; P =0.029; interaction P =0.054), driven mainly by lower AF recurrence (18.4% versus 42.4%, P =0.008). Spline analysis indicated a greater treatment benefit with increasing LVA size, reaching significance around 20 cm 2 . Conclusions: The efficacy of adjunctive LVA ablation increased with substrate size, with a significant benefit observed in patients with extensive LVAs. These findings support a substrate size–guided ablation strategy to optimize rhythm outcomes in persistent AF. Registration: URL: https://www.umin.ac.jp/ctr ; Identifier: UMIN000035940.


  • Open Access

    Differential Impact of Low Voltage Area Radiofrequency Ablation on Recurrence of Atrial Fibrillation Versus Atrial Tachycardia in Patients With Persistent Atrial Fibrillation

    by Daisuke Sakamoto, Akihiro Sunaga, Yuki Matsuoka, Hideaki Hasegawa, Hirota Kida, Tomoharu Dohi, Daisaku Nakatani, Katsuki Okada, Tetsuhisa Kitamura, Masaharu Masuda, et al.


  • Open Access

    Win ratio analysis of low-voltage area ablation in persistent atrial fibrillation: sub-analysis of SUPPRESS-AF

    by Akihiro Sunaga, Yuki Matsuoka, Daisaku Nakatani, Katsuki Okada, Daisuke Sakamoto, Hideaki Hasegawa, Tetsuhisa Kitamura, Masaharu Masuda, Nobuaki Tanaka, Tetsuya Watanabe, et al.

    Aims: In persistent atrial fibrillation (AF), low-voltage areas (LVAs) in the left atrium are considered arrhythmogenic. Although substrate ablation targeting LVAs may reduce AF recurrence, its effect on broader clinical outcomes remains unclear, and procedural risks must be considered. This study aims to compare hierarchical clinical outcomes between pulmonary vein isolation (PVI) alone and PVI plus LVA ablation in patients with persistent AF and LVAs using a win ratio analysis. Methods and results: This was a post hoc sub-analysis of the SUPPRESS-AF trial, including 341 patients with LVAs out of 1364 randomized. Patients received either PVI alone (n = 171) or PVI with LVA ablation (n = 170). Hierarchical outcomes were analysed in order of clinical importance: all-cause death, symptomatic stroke, AF recurrence, bleeding, and periprocedural complications. Win ratio analysis was used for comparison. Baseline characteristics were balanced between groups. The PVI plus LVA group had longer procedure times and higher energy delivery. The win ratio analysis showed no significant difference between groups (win ratio: 1.01, 95% confidence interval: 0.73–1.39, P = 0.940). The PVI-alone group had numerically fewer adverse events, while the LVA ablation group showed a numerical reduction in AF recurrence. Subgroup analyses showed consistent findings. Conclusion: In patients with persistent AF and LVAs, LVA ablation added to PVI did not improve hierarchical clinical outcomes and prolonged procedures. Routine use of current LVA ablation strategies is not supported, though targeted substrate modification may warrant further research. Registration: UMIN-CTR, https://www.umin.ac.jp/ctry. UMIN000035940.


  • Open Access

    Efficacy of Low-Voltage-Area Ablation Is Enhanced in Patients With Advanced Left Atrial Enlargement: A Subanalysis of the SUPPRESS-AF Trial

    by Masaharu Masuda, Yasuhiro Matsuda, Hiroyuki Uematsu, Hirotaka Ooka, Satoshi Kudo, Mizuki Ochi, Toshiaki Mano, Akihiro Sunaga, Nobuaki Tanaka, Tetsuya Watanabe, et al.

    BACKGROUND: In the randomized controlled SUPPRESS-AF trial (Efficacy and Safety of Left Atrial Low-voltage Area Guided Ablation for Recurrence Prevention Compared to Pulmonary Vein Isolation Alone in Patients with Persistent Atrial Fibrillation), the efficacy of low-voltage-area (LVA) ablation was highly dependent on the degree of atrial remodeling, while the efficacy was not statistically significant in total patients. This subanalysis of the SUPPRESS-AF trial aimed to compare the efficacy of LVA ablation in patient groups classified by left atrial diameter (LAD), which is a commonly used atrial remodeling index. METHODS: The SUPPRESS-AF trial included patients with persistent AF and left atrial LVAs, and compared rhythm outcomes between patients randomized to undergo pulmonary vein isolation (PVI) followed by left atrial LVA ablation group (n=170) or PVI-alone group (n=172). In this post hoc subanalysis, patients in each of the 2 randomly allocated groups were further divided into 2 groups using a median LAD of 44 mm. RESULTS: Atrial fibrillation or atrial tachycardia recurrence–free rates did not differ between patients with LAD>44 mm and ≤44 mm (60.1% versus 53.7%; P =0.261). Among patients with a LAD>44 mm, the LVA ablation group demonstrated a higher atrial fibrillation or atrial tachycardia-recurrence–free rate than the PVI-alone group (62.5% versus 43.4%; P =0.016). In contrast, no difference in atrial fibrillation or atrial tachycardia recurrence–free rate was found between the 2 groups of patients with a LAD≤44 mm (60.8% versus 59.6%; P =0.986). CONCLUSIONS: The efficacy of LVA ablation in addition to PVI for the treatment of persistent AF was more pronounced in patients with a large left atrium. REGISTRATION: URL: https://www.umin.ac.jp/ctr ; Unique identifier: UMIN000035940.